scispace - formally typeset
A

Alison C. MacKinnon

Researcher at University of Edinburgh

Publications -  96
Citations -  6665

Alison C. MacKinnon is an academic researcher from University of Edinburgh. The author has contributed to research in topics: Galectin-3 & Idiopathic pulmonary fibrosis. The author has an hindex of 35, co-authored 87 publications receiving 5734 citations.

Papers
More filters
Journal ArticleDOI

Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: A mechanism for small cell lung cancer growth and drug resistance in vivo

TL;DR: It is shown here that SCLC is surrounded by an extensive stroma of extracellular matrix (ECM) at both primary and metastatic sites, which enhances tumorigenicity and confers resistance to chemotherapeutic agents as a result of β1 integrin-stimulated tyrosine kinase activation suppressing chemotherapy-induced apoptosis.
Journal ArticleDOI

Galectin-3 regulates myofibroblast activation and hepatic fibrosis

TL;DR: In vivo siRNA knockdown of Galectin-3 inhibited myofibroblast activation after hepatic injury and may therefore provide an alternative therapeutic approach to the prevention and treatment of liver fibrosis.
Journal ArticleDOI

Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis.

TL;DR: It is demonstrated for the first time that galectin-3 expression and secretion by macrophages is a major mechanism linking macrophage to the promotion of renal fibrosis.
Journal ArticleDOI

Regulation of Alternative Macrophage Activation by Galectin-3

TL;DR: In this paper, a siRNA-targeted deletion of the galectin-3 gene in 129 mice specifically restrains IL-4/IL-13-induced alternative macrophage activation in bone marrow-derived macrophages.
Journal ArticleDOI

Regulation of Transforming Growth Factor-beta 1-driven Lung Fibrosis by Galectin-3

TL;DR: This study identifies galectin-3 as an important regulator of lung fibrosis and provides a proof of principle for galectine-3 inhibition as a potential novel therapeutic strategy for IPF.